DoD PRMRP Focused Program Award | W81XWH 22 PRMRP FPA

Opportunity Information: Apply for W81XWH 22 PRMRP FPA

The DoD PRMRP Focused Program Award (FPA), issued under FY22 by the Department of Defense through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is designed to speed progress on a high-impact medical research problem by funding a coordinated, team-based program rather than a single standalone study. The central idea is to optimize research efforts and accelerate solutions to a critical question that fits within one of the congressionally directed FY22 PRMRP Topic Areas and aligns with one of the FY22 PRMRP Strategic Goals. In practical terms, the program is looking for applicants to propose a tightly integrated set of projects that, when executed together, can move a field forward faster and more decisively than separate, unconnected grants.

A defining requirement of this opportunity is the need for a clearly articulated "overarching challenge." Applicants must describe one unifying, big-picture problem statement that anchors the entire program and reflects a meaningful gap in research and/or patient care. This overarching challenge is not meant to be a vague theme; it should be framed as a concrete critical question or problem that matters clinically or scientifically within the specified PRMRP topic and strategic framework. The proposed program should make it easy for reviewers to see why the challenge is urgent, what success would look like, and how the program structure is intentionally built to achieve that success.

To address that overarching challenge, the FPA expects applicants to propose multiple distinct research projects, each led by its own project leader. Applicants are strongly encouraged to include at least four research projects, with additional studies allowed if they are justified and contribute real value. Each project should tackle a different but complementary aspect of the overarching challenge, using different expertise, methods, or perspectives. While every project must stand on its own scientifically (meaning it should be rigorous and worthwhile even if viewed independently), the program places heavy emphasis on synergy: the projects should interlock in a way that creates added value, producing outcomes that would be difficult or impossible to achieve if the projects were funded and run separately. The announcement also encourages applicants to explore multiple hypotheses or viewpoints around the same general line of questioning, which supports multidisciplinary thinking and reduces the risk of locking into a single assumption too early.

At the same time, the award is not intended to fund a chain of studies where later projects only become viable if an earlier project succeeds. In other words, the portfolio should not be built like dominoes. Each project is expected to be a unique approach that can generate meaningful findings on its own, with the combined set accelerating progress toward the overarching goal. This structure is meant to keep the overall program resilient, so that even if one project runs into setbacks, the remaining projects can still produce impactful results and maintain momentum toward translation.

In terms of the types of work supported, the FPA allows a wide spectrum, from exploratory or hypothesis-generating research through small-scale clinical trials, up to and including Phase 2 (or equivalent). However, the program expects a clear intention to move toward translational and clinical impact over the course of the effort. For applicants proposing work that will require FDA regulatory permissions, the announcement calls out Investigational New Drug (IND) applications and Investigational Device Exemptions (IDE). If a project includes preclinical work intended to support an early-phase clinical trial (pilot, Phase 1, Phase 2, or equivalent), the application should include a proposed timeline for submitting the IND or IDE to the FDA, signaling that regulatory planning and clinical translation are being taken seriously from the outset.

Administratively, this opportunity (Funding Opportunity Number W81XWH 22 PRMRP FPA) is categorized as discretionary and can be funded through either a grant or a cooperative agreement, reflecting that some awards may involve closer coordination with the government depending on project needs. Eligibility is broadly "unrestricted," meaning it is open to essentially any type of entity unless additional eligibility clarifications are provided elsewhere in the full announcement. The CFDA number associated with this opportunity is 12.420. The original posting date was March 16, 2022, with an original closing date of August 12, 2022. The opportunity anticipated making about five awards. The listing shows an award ceiling of 0, which typically signals that applicants need to rely on the full announcement for budgeting limits or that a fixed ceiling is not specified in that particular data field.

Overall, the PRMRP Focused Program Award is structured for teams that can define a single, compelling, clinically relevant challenge and then execute a coordinated set of high-quality projects that are independent in scientific merit but intentionally designed to reinforce one another. The best fit is a multidisciplinary program that is engineered from the beginning to produce a translational payoff, with thoughtful project leadership, complementary approaches, and a credible path toward clinical application, including regulatory milestones when applicable.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD PRMRP Focused Program Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Aug 12, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRMRP FPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: